Teva Pharmaceutical | $TEVA Stock | Shares Rally After Winning FDA Approval for Migraine Therapy - Warrior Trading News
Teva abused patent system and spread misinformation about a Copaxone rival, European officials say
Teva shares plunge as competitors get nod for copycat flagship drug | The Times of Israel
Israel's Teva seeks to acquire drug manufacturer Mylan for $40 billion - The 5 Towns Jewish Times
Drug Maker Teva to Pay Over $500 Million in New York Drug Case Settlement - The New York Times
Teva's Israeli Plant Receives FDA Stamp of Approval for Migraine Drug Manufacturing | Ctech
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva faces class-action lawsuit over US antitrust probe into price-fixing | The Times of Israel
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Anything but Generic: A map for Selling to Teva Pharmaceuticals
What are the implications of a generic Teva MS drug? Here's what the wags say - STAT
Teva's CEO Shows He Means Business With Planned 25% Job Cuts - Bloomberg
Supreme Court rules for Teva over MS drug patent | Reuters.com
Teva Pharmaceuticals Q4 2016 Earnings
Analysts Split Over Buffett's Backing of Teva Pharma | BioSpace
Teva Pharmaceutical Stock: Stuck In A Cycle Of Hope And Disappointment | Seeking Alpha
Teva Pharmaceuticals considers laying-off 10,000 workers - The Jerusalem Post
Brand-name drug group accepts Teva, a maker of generics - The Boston Globe
Teva Pharmaceuticals - Wikiwand
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva knocked as competition fears grow for MS drug | Financial Times
Israeli drug company Teva reaches $4.3 billion settlement in US opioid lawsuits | The Times of Israel
Teva Pharmaceuticals - Wikipedia
EU antitrust authorities launch probe of Teva over Copaxone drug | The Times of Israel
A Drug Company Wagers the U.S. Won't Dare Charge It With Crimes - The New York Times
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
